Avadel Pharmaceuticals plc (AVDL) announced on Tuesday that 94 percent of patients in the RESTORE study who have narcolepsy preferred the once-nightly regimen of Lumryz over the twice-nightly Oxybate treatments.
According to the data, 91 percent of participants reported an improved ability to sleep through the night after transitioning to Lumryz. The U.S. FDA approved Lumryz in 2023 as the first and only once-nightly Oxybate for the treatment of cataplexy or excessive daytime sleepiness in adults with narcolepsy.
Furthermore, the company highlighted that 93 percent of patients who switched to Lumryz would recommend it to family or friends with the same condition.
Jennifer Gudeman, Senior Vice President of Medical and Clinical Affairs at Avadel, stated, "Data from the RESTORE study demonstrate that Lumryz is well tolerated, with a low rate of discontinuation due to adverse events. This further confirms the long-term safety and tolerability of this innovative treatment option."
Currently, Avadel's stock is trading at $15.49, marking a 2.11 percent increase on the Nasdaq.
